← Eichor
Condition: Anatomic Stage Iv Breast Cancer Ajcc V8 Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Anatomic Stage Iv Breast Cancer Ajcc V8

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Can
EARLY_Phase 1 · 1 location(s) · Ohio State University Comprehensive Cancer Center · NCT05417308Testing the Addition of Anti-Cancer Drug, ZEN003694 (ZEN-3694) and PD-1 Inhibitor (Pembrolizumab), to Standard Chemother
Phase 1 · 6 location(s) · National Cancer Institute (NCI) · NCT05422794Cemiplimab and Transarterial Radioembolization With Y-90 SIR-S Spheres for the Treatment of Liver Directed Metastatic Br
Phase 2 · 1 location(s) · City of Hope Medical Center · NCT06860815S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961Study of Screening Brain MRIs in Stage IV Breast Cancer
Phase 2 · 2 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05115474Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer
NA · 1 location(s) · Mayo Clinic · NCT05746325An Optimized Ultrasound Twinkling Marker for the Imaging of Lymph Nodes in Patients With Clinically Node-Positive Breast
Phase 1 · 1 location(s) · Mayo Clinic · NCT06999798An Investigational Scan (64Cu-DOTA-Trastuzumab PET/MRI) in Imaging Patients With HER2+ Breast Cancer With Brain Metastas
Phase 4 · 1 location(s) · City of Hope Medical Center · NCT05376878DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients
Phase N/A · 1 location(s) · Mayo Clinic · NCT06388122A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
Phase 1 · 1 location(s) · Mayo Clinic · NCT04521764A Cancer Vaccine (STEMVAC) in Combination With Chemotherapy for the Treatment of PD-L1 Negative Metastatic Triple-Negati
Phase 2 · 1 location(s) · University of Washington · NCT07078604Enhancing Access to Supportive Services for Women of Color With Metastatic Breast Cancer
NA · 1 location(s) · Icahn School of Medicine at Mount Sinai · NCT06405828High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metast
Phase 2 · 1 location(s) · Emory University · NCT06492759SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Phase N/A · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT00899301Investigating the Feasibility and Acceptability of an Innovative Interdisciplinary Supportive Care Program: Couples Copi
Phase N/A · 1 location(s) · City of Hope Medical Center · NCT07664579Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metas
Phase 2 · 30 location(s) · National Cancer Institute (NCI) · NCT03606967CATCH: Implementation of Genomics-guided Precision Medicine in Metastatic Breast Cancer
Phase N/A · 12 location(s) · German Cancer Research Center · NCT05652569Stereotactic Body Radiation Therapy and FES PET/CT Imaging for the Treatment of Oligoprogressive Estrogen Receptor Posit
Phase 2 · 2 location(s) · City of Hope Medical Center · NCT06260033Mobile Health for Adherence in Breast Cancer Patients
NA · 506 location(s) · ECOG-ACRIN Cancer Research Group · NCT06112613Testing the Safety of the Combination of Anti-Cancer Drugs CX-5461 (Pidnarulex) and Trastuzumab Deruxtecan (T-DXd) for H
Phase 1 · 2 location(s) · National Cancer Institute (NCI) · NCT07137416Adaptive Therapy With Capecitabine for Treatment of Metastatic ER Positive, HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Mayo Clinic · NCT06525766Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast Cancer
Phase 2 · 1 location(s) · University of Louisville · NCT04990921Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer
Phase N/A · 1 location(s) · Mayo Clinic · NCT04517838Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT04771520Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
Phase N/A · 1 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT01000883A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Recept
Phase 2 · 1 location(s) · University of Washington · NCT07112053Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (D
Phase 1/Phase 2 · 1 location(s) · Margaret Gatti-Mays · NCT06026657Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Canc
Phase 1 · 4 location(s) · Emory University · NCT06324240
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.